IGC Pharma因其数据整合AI工具AHA获得1M阿尔茨海默氏氏性阿尔茨海默症AI奖半决赛。 IGC Pharma reached the semi-finals of the $1M Alzheimer’s AI Prize for its data-integrating AI tool, AHA.

IGC Pharma的AI项目“AHA:代理协调助理”获得了100万美元的阿尔茨海默氏综合观察AI奖半决赛,该项目应对了阿尔茨海默氏研究中的数据整合挑战。 IGC Pharma has advanced to the semi-finals of the $1 million Alzheimer's Insights AI Prize for its AI project "AHA: Agentic Harmonization Assistant," which tackles data integration challenges in Alzheimer’s research. 该工具以IGC的MINT-AD平台为基础,统一了临床、成像、遗传和生活方式数据,以加速药物发现和试验设计。 The tool, built on IGC’s MINT-AD platform, unifies clinical, imaging, genetic, and lifestyle data to accelerate drug discovery and trial design. 该公司在第二阶段试验中开发IGC-AD1等AI驱动疗法,将于2025年12月5日在圣地亚哥介绍其工作。 The company, developing AI-driven therapies like IGC-AD1 in a Phase 2 trial, will present its work in San Diego on December 5, 2025. 这种认识反映出产业界越来越重视人工智能,以推动阿尔茨海默氏病的治疗发展。 The recognition reflects rising industry focus on agentic AI to advance Alzheimer’s treatment development.